Jpmorgan Chase & CO Harmony Biosciences Holdings, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding HRMY
# of Institutions
229Shares Held
45.1MCall Options Held
48.2KPut Options Held
56.5K-
Valor Management LLC Chicago, IL11.2MShares$371 Million100.0% of portfolio
-
Black Rock Inc. New York, NY5.84MShares$193 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.52MShares$116 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.61MShares$86.1 Million11.62% of portfolio
-
Pacer Advisors, Inc. Malvern, PA2.51MShares$82.9 Million0.19% of portfolio
About Harmony Biosciences Holdings, Inc.
- Ticker HRMY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,161,400
- Market Cap $1.96B
- Description
- Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...